Gufic BioSciences Ltd

Gufic BioScience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Gufic BioSciences Ltd

₹ 334 2.44%
29 May - close price
gufic.com BSE: 509079 NSE: GUFICBIO
About

Gufic Biosciences Limited is engaged in the manufacture of pharmaceuticals, medicinal chemicals and botanical products.

Key Points

Business Segments
1) Domestic Branded Business: The company develops pharmaceutical formulations in various forms, including injectables, syrups, ointments, lotions, and herbal products. It serves 15+ therapeutic areas, including critical care, infertility, nutraceuticals, etc with a portfolio of 100+ products, 200+ SKUs, and a network of 30,000+ prescribers. It is one of the largest manufacturers of Lyophilized Injections in India. The company aims to expand into Biologicals and Immuno-Oncology. [1] [2]

Website BSE NSE
  • Market Cap ₹ 3,348 Cr.
  • Current Price ₹ 334
  • High / Low ₹ 409 / 268
  • Stock P/E 53.0
  • Book Value ₹ 66.2
  • Dividend Yield 0.03 %
  • ROCE 12.2 %
  • ROE 9.98 %
  • Face Value ₹ 1.00
Edit ratios

Pros

Cons

  • Stock is trading at 5.04 times its book value
  • Company has a low return on equity of 13.5% over last 3 years.
  • Dividend payout has been low at 0.87% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Healthcare BSE 1000

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026
173 195 215 202 195 203 204 208 205 227 230 231 252
141 160 176 165 161 167 166 174 178 195 195 195 206
Operating Profit 32 35 39 36 34 36 39 34 27 32 36 36 46
OPM % 19% 18% 18% 18% 18% 18% 19% 16% 13% 14% 16% 16% 18%
1 1 0 0 1 1 0 2 0 1 2 1 -1
Interest 3 4 4 3 4 5 5 5 8 9 10 8 9
Depreciation 6 4 4 4 4 4 4 5 8 8 8 8 8
Profit before tax 24 28 31 30 27 28 29 26 11 16 21 21 28
Tax % 24% 26% 25% 25% 26% 26% 26% 26% 26% 26% 27% 26% 26%
18 21 23 22 20 21 22 19 8 12 15 16 21
EPS in Rs 1.87 2.13 2.39 2.22 2.00 2.08 2.17 1.93 0.79 1.20 1.49 1.55 2.05
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
148 201 245 306 351 379 488 779 691 807 820 940
134 181 222 267 305 327 404 631 556 657 683 790
Operating Profit 14 20 23 39 46 52 84 148 135 150 136 150
OPM % 10% 10% 9% 13% 13% 14% 17% 19% 20% 19% 17% 16%
1 1 1 4 4 6 4 3 3 -0 4 3
Interest 4 6 6 9 10 14 14 5 8 17 25 37
Depreciation 4 4 4 4 5 14 16 19 22 17 21 31
Profit before tax 7 10 14 30 35 30 58 127 107 116 94 85
Tax % 36% 29% 37% 45% 38% 25% 23% 24% 25% 26% 26% 26%
4 7 9 16 22 23 44 96 80 86 70 63
EPS in Rs 0.54 0.95 1.17 2.13 2.82 2.92 5.68 9.89 8.22 8.59 6.97 6.30
Dividend Payout % 9% 5% 4% 2% 2% 2% 2% 1% 1% 1% 1% 0%
Compounded Sales Growth
10 Years: 17%
5 Years: 14%
3 Years: 11%
TTM: 15%
Compounded Profit Growth
10 Years: 24%
5 Years: 7%
3 Years: -7%
TTM: -10%
Stock Price CAGR
10 Years: 23%
5 Years: 13%
3 Years: 19%
1 Year: -15%
Return on Equity
10 Years: 20%
5 Years: 18%
3 Years: 13%
Last Year: 10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Equity Capital 8 8 8 8 8 10 10 10 10 10 10 10
Reserves 19 26 30 46 68 120 164 259 338 523 591 654
33 43 57 80 98 126 62 64 334 333 336 405
67 75 84 104 106 152 157 188 179 227 232 273
Total Liabilities 127 152 178 238 280 408 392 521 861 1,093 1,170 1,342
25 22 22 23 24 83 100 115 160 159 506 491
CWIP 0 0 0 2 10 31 13 41 170 307 22 22
Investments 0 0 0 0 0 0 0 0 1 2 3 3
102 130 156 213 245 294 279 365 531 625 639 826
Total Assets 127 152 178 238 280 408 392 521 861 1,093 1,170 1,342

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
11 -4 -4 -5 5 47 87 106 -27 -7 123
-2 -1 -5 -9 -13 -43 -7 -95 -191 -102 -72
-5 5 7 14 8 -4 -79 -6 234 82 -37
Net Cash Flow 4 -0 -1 1 -0 0 2 5 17 -27 14
Free Cash Flow 9 -5 -8 -13 -8 7 75 19 -214 -116 52
CFO/OP 92% -8% 2% 30% 33% 110% 115% 94% 1% 13% 107%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Debtor Days 82 102 78 97 107 103 93 71 109 149 140 115
Inventory Days 165 180 190 238 190 249 138 102 202 188 211 281
Days Payable 223 188 132 192 157 238 162 125 143 156 155 173
Cash Conversion Cycle 25 94 136 143 141 114 69 48 167 181 197 224
Working Capital Days 4 18 14 26 40 17 63 50 68 97 93 81
ROCE % 18% 24% 24% 33% 30% 21% 29% 46% 23% 17% 13% 12%

Insights

In beta
Mar 2015 Jun 2021 Mar 2023 Mar 2024 Sep 2025
Products Registered Globally
Count

Log in to view insights

Please log in to see hidden values.

Login
Total Employees/Workers
Count
Total Field Force
Count
Lyophilized Vials Installed Capacity (Navsari Unit I + II)
mn vials p.a.
Research & Development Spend
Rs. Lakhs
Installed Capacity - Indore Unit III (Liquid Ampoules)
mn units p.a.
Installed Capacity - Indore Unit III (Lyophilized Injections)
mn vials p.a.
Retail Reach
Count
Doctor Reach
Count
Patents Granted
Count
Total SKUs
Count

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
75.00% 75.00% 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.50% 72.50% 72.50%
0.70% 0.72% 0.47% 0.12% 0.23% 0.23% 0.30% 0.31% 0.32% 0.33% 0.44% 0.42%
1.16% 1.63% 1.72% 2.20% 2.38% 2.51% 2.99% 3.39% 3.38% 3.66% 3.74% 3.83%
23.12% 22.64% 25.29% 25.17% 24.89% 24.75% 24.20% 23.79% 23.81% 23.51% 23.30% 23.23%
No. of Shareholders 38,62436,55734,42434,69532,25032,82533,29931,84431,87631,42030,36229,223

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls